News from mallinckrodt plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Jun 01, 2023, 06:52 ET Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the presentation of results from two clinical...

May 09, 2023, 06:45 ET Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance

Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First...

May 08, 2023, 06:52 ET Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at Digestive Disease Week (DDW) 2023

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the presentation of results from two clinical...

May 05, 2023, 06:52 ET Mallinckrodt Recognized as Industry Innovator at National Organization for Rare Disorders (NORD) 2023 Rare Impact Awards

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, is pleased to announce it has received an award from the National...

Apr 24, 2023, 06:45 ET Mallinckrodt to Report Earnings Results for First Quarter 2023

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that it will report first quarter 2023 earnings...

Apr 10, 2023, 06:53 ET Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the National Kidney Foundation (NKF) 2023 Spring Clinical Meeting (SCM)

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that two scientific abstracts on the clinical and...

Mar 21, 2023, 06:53 ET Mallinckrodt to Present New Retrospective Data on Effect of Acthar® Gel (Repository Corticotropin Injection) to Reduce Corticosteroid Use and Burden for Advanced Sarcoidosis at the Academy of Managed Care Pharmacy (AMCP) 2023 Annual Meeting

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that an abstract highlighting results from a...

Mar 09, 2023, 07:51 ET Mallinckrodt ilmoittaa ekstrakorporaalisen fotofereesijärjestelmän (ECP) korvaushyväksynnästä Japanissa CELLEX® kroonisen käänteishyljintäsairaudesta (cGvHD) hoidossa

Mar 09, 2023, 07:37 ET Mallinckrodt kunngjør godkjenning av refusjon i Japan for CELLEX® ekstrakorporal fotoferese (ECP) system for behandling av kronisk graft versus host disease (kGVHD)

Mar 09, 2023, 06:34 ET Mallinckrodt: CELLEX® Extracorporeal Photopheresis (ECP) System godkendt som refusionsberettiget i den nationale sundhedssikring i Japan for behandling af kronisk GvHD (Graft Versus Host Disease)

Mar 09, 2023, 03:00 ET A Mallinckrodt anuncia aprovação de reembolso no Japão para o sistema de fotoferese extracorpórea (FEC) CELLEX® destinado ao tratamento da doença crónica do enxerto contra o hospedeiro (DECHc)

Mar 09, 2023, 03:00 ET Mallinckrodt Announces Reimbursement Approval in Japan for the CELLEX® Extracorporeal Photopheresis (ECP) System for the Treatment of Chronic Graft Versus Host Disease (cGvHD)

Mar 09, 2023, 02:00 ET Mallinckrodt gibt Genehmigung der Kostenerstattung in Japan für CELLEX® Extrakorporales Photopherese (ECP) -System zur Behandlung der chronischen Graft Versus Host Disease (dt. Transplantat-gegen-Wirt-Reaktion, cGvHD) bekannt

Mar 09, 2023, 02:00 ET Mallinckrodt annuncia l'approvazione del rimborso in Giappone per il sistema di fotoforesi extracorporea (ECP) CELLEX® per il trattamento della malattia da trapianto contro l'ospite cronica (cGvHD)

Mar 09, 2023, 02:00 ET Mallinckrodt anuncia la aprobación del reembolso en Japón del sistema de fotoféresis extracorpórea CELLEX®

Mar 09, 2023, 02:00 ET Mallinckrodt annonce l'autorisation de remboursement au Japon du système de photophérèse extracorporelle CELLEX® pour le traitement de la maladie chronique du greffon contre l'hôte (MGCHc)

Mar 09, 2023, 02:00 ET Mallinckrodt ogłasza zatwierdzenie refundacji w Japonii dla systemu do fotoferezy pozaustrojowej (ECP) CELLEX® przeznaczonego do leczenia chronicznego schorzenia przeszczep przeciwko gospodarzowi (cGvHD)

Feb 28, 2023, 06:45 ET Mallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 Guidance

Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the...

Feb 16, 2023, 08:03 ET Mallinckrodt to Present at Cowen's 43rd Annual Health Care Conference

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that Siggi Olafsson, President and Chief Executive...

Feb 08, 2023, 06:45 ET Mallinckrodt to Report Earnings Results for Fourth Quarter 2022

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that it will report fourth quarter 2022 earnings...

Jan 22, 2023, 14:00 ET Mallinckrodt Presents New TERLIVAZ® (terlipressin) for Injection Data on Hepatorenal Syndrome (HRS) Reversal at the Society of Critical Care Medicine (SCCM) 2023 Critical Care Congress

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the presentation of results from a retrospective...

Jan 12, 2023, 06:45 ET Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer

Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr. Peter...

Nov 16, 2022, 06:52 ET Mallinckrodt Announces 2022 Advancing Extracorporeal Photopheresis Immunomodulation Investigator Award

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the recipient of 2022's Advancing Extracorporeal...

Nov 08, 2022, 06:45 ET Mallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms Guidance

Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the...

Nov 03, 2022, 06:53 ET Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that seven scientific abstracts on clinical and...